Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes – which play a central role in the body’s immune response – with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA (miRNA). The achievement in mice studies may be the first step toward using genetically modified miRNA for therapeutic purposes, perhaps most notably in vaccines and cancer treatments, said principal investigator Maurizio Zanetti, MD, professor in the Department of Medicine and director of the Laboratory of Immunology at UC San Diego Moores Cancer Center. Read more here.
Study mentioned: Almanza G, et al. Synthesis and delivery of short, noncoding RNA by B lymphocytes. PNAS. Published online before print November 25, 2013.
No comments:
Post a Comment